Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedSpas of America acquires skin care line
According to MedSpas of America, its all-natural products contain a uniquely exotic and effective combination of hibiscus flower and kukui nut oil. The company will immediately re-brand this
According to MedSpas of America, its all-natural products contain a uniquely exotic and effective combination of hibiscus flower and kukui nut oil. The company will immediately re-brand this
The business will be renamed Cambrex Tallinn after completion of the acquisition. Cambrex intends to add more process and analytical chemists at the site and continue early active
Baxter will develop both an unmodified recombinant Factor IX therapy for treatment of acute bleeding episodes and a chemically modified, long-acting version of recombinant Factor IX therapy for
The study has met its primary endpoint of a statistically significant reduction in incontinence episodes, and secondary endpoints of reduction in frequency and increases in void volume compared
As part of the strategic relationship, Genzyme will also have preferred access to future Isis drugs for central nervous system and certain rare diseases. Genzyme will pay Isis
This Phase Ib study was designed to assess the safety, tolerability and pharmacokinetics of once-daily, orally administered doses of either 2.5gm or 5gm of SRT501 in patients with
CoMentis said that pharmacodynamic proof of activity was achieved as subjects displayed a robust, sustained and dose-related reduction in plasma amyloid beta in both area-under-curve (AUC) reduction and
Breckenridge expects to file an abbreviated new drug application (ANDA) with the FDA in January 2008. Upon approval by the FDA, Helm will supply and Breckenridge will market
APD668 is an oral drug candidate discovered by Arena and being investigated under a partnership with Ortho-McNeil Pharmaceutical. Ortho-McNeil’s initial clinical studies evaluated healthy volunteers and patients with
The study is designed to demonstrate that the single-injection Monovisc safely provides symptomatic relief of knee pain and associated dysfunction in patients with osteoarthritis. Anika plans to enroll